Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease

被引:1
|
作者
Carvello, Michele [1 ,2 ]
Danese, Silvio [1 ,3 ]
Spinelli, Antonino [1 ,2 ]
机构
[1] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[2] IRCCS Humanitas Res Hosp, Div Colon & Rectal Surg, Milan, Italy
[3] IRCCS Humanitas Res Hosp, IBD Ctr, Dept Gastroenterol, Milan, Italy
关键词
surgery; ileocectomy; Crohn's disease; top-down; INFLAMMATORY-BOWEL-DISEASE; EARLY COMBINED IMMUNOSUPPRESSION; MAGNETIC-RESONANCE; TERMINAL ILEITIS; EUROPEAN CROHNS; MANAGEMENT; RESECTION; INFLIXIMAB; HOSPITALIZATION; MULTICENTER;
D O I
10.1055/s-0041-1740031
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The deeper understanding of the inflammatory process which gradually evolves into irreversible fibrosis and tissue damage has provided a precise picture of the disease course of luminal ileocecal Crohn's disease. According to the model of progressive structural damage, ideal time windows for medical and surgical treatment have been identified. While complicated disease clearly profits from surgical treatment, uncomplicated disease has become, in the last years, the most debatable setting in terms of different approaches including early surgery. On one hand, the rationale of traditional escalating medical therapy (step-up approach) has been undermined by the top-down medical approach. Indeed, the step-up approach has the possible drawback of delaying, up to a later disease stage, the use of more effective agents such as anti-tumor necrosis factors. Conversely, the top-down approach might expose patients to an overtreatment along with side effects including hypersensitivity to biologic agents. More recently, it has been shown how early surgery could be a valid option in this subset of patients being more cost-effective than medical therapy. Involving the surgeon at an early stage is considered now a good clinical practice and, in this scenario full of possibilities, the surgeon should be included into the decision-making process from the very beginning of patient management.
引用
下载
收藏
页码:72 / 77
页数:6
相关论文
共 50 条
  • [41] Advances in medical therapy for Crohn's disease.
    D'Haens G.
    Daperno M.
    Current Gastroenterology Reports, 2002, 4 (6) : 506 - 512
  • [42] Medical therapy for refractory pediatric Crohn's disease
    Faubion, William A., Jr.
    Bousvaros, Athos
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (10) : 1199 - 1213
  • [43] Medical therapy of small bowel Crohn's disease
    Irvine, E. J.
    EMERGING ISSUES IN INFLAMMATORY BOWEL DISEASES, 2006, 151 : 181 - 188
  • [44] Approach to medical therapy in perianal Crohn's disease
    Vasudevan, Abhinav
    Bruining, David H.
    Loftus, Edward V., Jr.
    Faubion, William
    Ehman, Eric C.
    Raffals, Laura
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (25) : 3693 - 3704
  • [45] Practical Application of Anti-TNF Therapy for Luminal Crohn's Disease
    Kamm, Michael A.
    Ng, Siew C.
    De Cruz, Peter
    Allen, Patrick
    Hanauer, Stephen B.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (11) : 2366 - 2391
  • [46] Surgery results in significant improvement in growth in children with Crohn's disease refractory to medical therapy
    Ranger, GS
    Lamparelli, MJ
    Aldridge, A
    Chong, SK
    Mitton, SG
    Albanese, A
    Kumar, D
    PEDIATRIC SURGERY INTERNATIONAL, 2006, 22 (04) : 347 - 352
  • [47] Surgery results in significant improvement in growth in children with Crohn’s disease refractory to medical therapy
    Gurpreet Singh Ranger
    Michael J. Lamparelli
    Andrew Aldridge
    Sonny K. Chong
    Sally G. Mitton
    Assunta Albanese
    Devinder Kumar
    Pediatric Surgery International, 2006, 22 : 347 - 352
  • [48] Medical therapy of Crohn disease
    Panaccione, R
    Sandborn, WJ
    CURRENT OPINION IN GASTROENTEROLOGY, 2004, 20 (04) : 351 - 359
  • [49] Infliximab use in luminal Crohn's disease
    Richter, James A.
    Bickston, Stephen J.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2006, 35 (04) : 775 - +
  • [50] Intestinal Fibrosis in Crohn's Disease: Medical Treatment or Surgery?
    Spinelli, Antonino
    Correale, Carmen
    Szabo, Hajnalka
    Montorsi, Marco
    CURRENT DRUG TARGETS, 2010, 11 (02) : 242 - 248